Oseltamivir
- Generic Name
- Oseltamivir
- Brand Names
- Ebilfumin, Tamiflu
- Drug Type
- Small Molecule
- Chemical Formula
- C16H28N2O4
- CAS Number
- 196618-13-0
- Unique Ingredient Identifier
- 20O93L6F9H
- Background
Oseltamivir (marketed as the product TamifluⓇ), is an antiviral neuraminidase inhibitor used for the treatment and prophylaxis of infection with influenza viruses A (including pandemic H1N1) and B. Oseltamivir exerts its antiviral activity by inhibiting the activity of the viral neuraminidase enzyme found on the surface of the virus, which prevents budding f...
- Indication
According to FDA prescribing information, oseltamivir is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours . In particular, this agent is indicated in adults and children including full-term neonates who present with symptoms ...
- Associated Conditions
- Flu caused by Influenza, Influenza A Virus Infection, Influenza A, Influenza B, Influenza Type B
- Associated Therapies
- -
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
- First Posted Date
- 2011-03-15
- Last Posted Date
- 2019-02-05
- Target Recruit Count
- 716
- Registration Number
- NCT01314911
- Locations
- 🇺🇸
East Valley Family Physicians, Chandler, Arizona, United States
🇺🇸Horizon Research Group of Opelousas, LLC, Eunice, Louisiana, United States
🇺🇸Michael Seep, MD; Centex Studies, Lake Charles, Louisiana, United States
A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT01258530
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Effect of Oseltamivir on Cognitive Function in Subjects With Influenza
- First Posted Date
- 2010-11-30
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Trial Management Group Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT01249833
- Locations
- 🇨🇦
Topsail Road Medical Clinic, St. John's, Newfoundland and Labrador, Canada
🇨🇦Family First Medical Centre, Orleans, Ontario, Canada
🇨🇦Moran Medical Centre, Collingwood, Ontario, Canada
Rapid Empiric Treatment With Oseltamivir Study (RETOS)
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- University of Louisville
- Target Recruit Count
- 1107
- Registration Number
- NCT01248715
- Locations
- 🇺🇸
Norton Hospital, Louisville, Kentucky, United States
🇺🇸Rex Robley VA Medical Center, Louisville, Kentucky, United States
🇺🇸Baptist Hospital East, Louisville, Kentucky, United States
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
- Conditions
- Interventions
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 626
- Registration Number
- NCT01231620
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
- Conditions
- Interventions
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2019-02-04
- Target Recruit Count
- 881
- Registration Number
- NCT01227967
- Locations
- 🇺🇸
Research Integrity, LLC, Owensboro, Kentucky, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
🇦🇷Hospital Rawson, Cordoba, Argentina
Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Manjunath Prakash Pai
- Target Recruit Count
- 21
- Registration Number
- NCT01179919
- Locations
- 🇺🇸
TKL Research, Paramaus, New Jersey, United States
Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment
- Conditions
- Interventions
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2013-08-21
- Lead Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01146535
- Locations
- 🇨🇳
Chang Gung Medical Foundation, LinKou Branch, Guishan, Taoyuan County, Taiwan
🇨🇳Show-Chwan Memorial Hospital, Changhua, Taiwan
🇨🇳Taiwan Municipal Hospital, Tainan, Taiwan
Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza During Lactation
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2012-10-08
- Lead Sponsor
- Pharmahungary Group
- Target Recruit Count
- 6
- Registration Number
- NCT01130636
- Locations
- 🇭🇺
DEOEC University of Debrecen, Clinic of Obstetrics and Gynecology, Debrecen, Hungary
🇭🇺Selye János Hospital, Department of Obstetrics and Gynecology, Komárom, Hungary
A Study on Higher-dose Oseltamivir Treatment's Impact on Viral Clearance and Clinical Recovery in Adults Hospitalized With Influenza
- First Posted Date
- 2010-01-21
- Last Posted Date
- 2012-07-20
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 157
- Registration Number
- NCT01052961
- Locations
- 🇭🇰
The Chinese University of Hong Kong, Prince of Wales Hospital and Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hksar, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.